文献速递肿瘤 PET/CT放射性药物与辐射防护

68Ga-前列腺特异性膜抗原PET/CT在卵巢肿瘤中的应用:术前鉴别良恶性肿瘤的潜力:初步报告

68 Ga-Prostate-Specific Membrane Antigen PET/CT in Ovarian Tumors : Potential to Differentiate Benign and Malignant Tumors Before Surgery: A Preliminary Report.
PubMed 文献 · Clin Nucl Med · 2022-11-18

这项初步研究纳入8例平均年龄56.0±16.2岁的女性,评估68Ga-PSMA-11 PET/CT在卵巢肿瘤术前检测中的可行性。3例(37.5%)PET/CT阳性,组织学证实2例为浆液性卵巢癌、1例为卵巢交界性肿瘤;5例(62.5%)阴性者组织病理证实为良性盆腔肿瘤。初步经验支持68Ga-PSMA-11在卵巢癌术前鉴别良恶性肿瘤方面的潜力。

要点

  • 8例女性卵巢肿瘤患者术前接受68Ga-PSMA-11 PET/CT检查。
  • 3例(37.5%)阳性,组织学证实为2例浆液性卵巢癌和1例交界性肿瘤。
  • 5例(62.5%)阴性者组织病理均证实为良性盆腔肿瘤。

核心结论

  • 初步经验支持68Ga-PSMA-11在卵巢癌术前鉴别良恶性肿瘤方面具有潜力。

研究设计与样本

  • 初步研究纳入8例女性,平均年龄56.0±16.2岁。
  • 所有患者先接受经阴道超声及胸部、腹部CT检查作为手术资格评估。
  • 在1周间隔内,注射2 MBq/kg 68Ga-PSMA-11后60分钟于Siemens Biograph扫描仪上行PET/CT。
  • 本研究经华沙医科大学伦理委员会批准(KB/2/A/2018)。

主要发现

  • 3例(37.5%)68Ga-PSMA-11 PET/CT阳性,组织学证实2例为浆液性卵巢癌、1例为卵巢交界性肿瘤。
  • 浆液性卵巢癌的SUVmax分别为8.7和4.1,交界性卵巢肿瘤的SUVmax为13.8。
  • 未发现抗原CA-125水平与68Ga-PSMA表达之间的相关性。
  • 肿瘤SUVmax范围与疾病分期无相关性。
  • 其余62.5%(5/8)68Ga-PSMA-11 PET/CT阴性,组织病理证实为良性盆腔肿瘤。

临床怎么用

  • 作者认为初步经验支持68Ga-PSMA-11在卵巢癌术前鉴别良恶性肿瘤方面具有潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF THE REPORT: Ovarian cancer is usually diagnosed in an advanced stage of disease due to the absence of specific symptoms and a lack of sensitive diagnostic methods. Prostate-specific membrane antigen (PSMA) is expressed on prostate cancer cells but can be found in other tumors such as ovarian cancer.The aim of this pilot study was to evaluate the feasibility of using 68 Ga-PSMA-11 PET/CT in detection of ovarian neoplasm before surgical treatment. PATIENTS AND METHODS: Eight women with mean age of 56.0 ± 16.2 years were included in the study. All patients underwent transvaginal ultrasound followed by CT scan of the chest and abdomen as qualification for surgery. Within a 1-week interval, PET/CT was performed on a Siemens Biograph scanner, 60 minutes after injection of 2 MBq/kg 68 Ga-PSMA-11. RESULTS: In 3 cases (37.5%), the 68 Ga-PSMA-11 PET/CT was positive, whereas histological examination confirmed 2 serous ovarian cancer cases and 1 ovarian borderline tumor. The SUV max in the serous ovarian cancer was 8.7 and 4.1, and in the borderline ovarian tumor, it was 13.8. No correlation was found between antigen CA-125 level and 68 Ga-PSMA expression. Range of tumor SUV max was not correlated with stage of disease. The remaining 62.5% (5/8) were negative in 68 Ga-PSMA-11 PET/CT, and histopathology confirmed benign pelvic tumor. CONCLUSIONS: The initial experience supports the potential to use 68 Ga-PSMA-11 in ovarian cancer to differentiate malignant and benign tumors before surgery.This study was approved by the Ethical Committee of the Medical University of Warsaw (KB/2/A/2018).

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kunikowska J, Bizoń M, Pełka K, et al. 68 Ga-Prostate-Specific Membrane Antigen PET/CT in Ovarian Tumors : Potential to Differentiate Benign and Malignant Tumors Before Surgery: A Preliminary Report. Clin Nucl Med. 2022. PMID: 36512649. doi:10.1097/RLU.0000000000004486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。